PHENOM
Phenom has been named a Strategic Leader in the 2023 Fosway 9-GridTM for Talent Acquisition for the third consecutive year, proving its ability to deliver higher levels of innovation, customer impact and advocacy compared to alternatives in the market. Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005161/en/
Strategic Leader position reaffirms Phenom and its Intelligent Talent Experience platform’s consistent ability to serve EMEA’s largest companies’ complex talent demands. (Graphic: Business Wire)
Job vacancy rates recently reached record highs and the competitive talent market remains a priority on the European Union’s policy agenda, according to a European Labour Authority report. To better connect with candidates and quickly fill open roles in a scalable, sustainable way, CHROs and CEOs from today’s leading enterprises are choosing holistic solutions that leverage intelligence, automation and experience to reduce repetitive tasks, increase recruiter efficiency and hyper-personalize every part of the talent journey.
“Artificial intelligence (AI) is accelerating disruption in the TA market,” said David Wilson, CEO, Fosway Group. “Phenom’s position as a Strategic Leader on the 2023 Fosway 9-Grid™ for Talent Acquisition reflects the company’s continued innovation in AI and the candidate and talent experience. Recent acquisitions continue to give the company even greater traction in the European market.”
More than 500 global, diverse enterprises use Phenom’s vast network of data, contextual industry models and deep learning to achieve measurable, defensible results. Case studies of customers using the Intelligent Talent Experience platform document their ability to:
- Generate 11X more internal and external applications and achieved a 50% reduction in time to apply
- Drive a 176% increase in applications and 165% increase in hires YOY
- Deliver 8X more candidates and 20% faster hires
- Save up to 78% of recruiters’ time with automated screening and scheduling
- Decrease time to schedule an interview 98% (from 5 minutes to 5 seconds) with automation
- Increase recruiter productivity 567% and reduce agency spend
- Cut 65 days off time to hire
“Phenom continues to deliver innovation, scale technology and elevate customer support to solve the most complex talent demands of the largest enterprises across Europe,” said Mahe Bayireddi, CEO and co-founder of Phenom. “We are fully invested in the success of our customers’ teams, their outcomes and the incredible impact they’re able to drive for talent acquisition and management — and the business as a whole.”
In addition to their existing talent acquisition technology — including Career Site, CMS, CRM, Video Assessments and AI Scheduling — Phenom recently announced Phenom X+, a new platform-wide generative AI capability that bolsters efficiencies by automating content creation, surfacing actionable intelligence, and eliminating time-consuming tasks. Phenom also unveiled 18 platform intelligence and automation innovations to further transform the way employers teams hire, develop and retain talent.
Platform innovation highlights include:
- Generative AI for TA — providing sourcers, recruiters, talent marketers, and other talent acquisition professionals the ability to generate personalized content that delights candidates and dramatically speeds up the hiring process by eliminating time-consuming, manual work.
- High-Volume Hiring — automating job discovery, application submission, and offering extension processes for frontline and hourly workers.
- Automation Engine — giving organizations the backend interface and control needed to configure and iterate on hiring workflows – complete with intelligence for ongoing monitoring and qualitative analysis of performance, plus recommendations to optimize in real-time.
- Interview Intelligence — eliminating the black box of the interview process by providing transcripts, key takeaways, and actionable guidance to the hiring team to move forward with decisions faster.
- Workforce Intelligence — providing context and oversight to HR teams within their organization, including hiring trends, churn rate, retention risks and high performers, to improve talent onboarding, development and retention.
- Candidate Hub – bringing transparency to candidates throughout the hiring process, making it easy to discover relevant roles, understand hiring status, prepare for interviews, and reschedule when conflicts arise.
Companies across EMEA are successfully adopting Phenom’s Intelligent Talent Experience platform to help candidates find and choose them faster, employees develop their skills and evolve, recruiters become wildly productive, managers build stronger-performing teams, HR align employee development with company goals and HRIS create a holistic tech infrastructure through seamless integrations.
To learn more about Phenom’s Strategic Leader position, read this blog.
To see the Phenom Intelligent Talent Experience platform in action, request a demo.
About the Fosway 9-Grid™
Fosway Group is Europe’s #1 HR industry analyst. The Fosway 9-Grid™ provides a unique assessment of the principal learning and talent supply options available to organizations in EMEA. The analysis is based on extensive independent research and insights from Fosway’s Corporate Research Network of over 250 organizations, including BP, HSBC, PwC, RBS, Sanofi, Shell, and Vodafone. Visit the Fosway website at www.fosway.com.
About Phenom
Phenom has a purpose of helping a billion people find the right job. Through AI-powered talent experiences, employers are using Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, hiring managers, HR and HRIS — empowering over 500 diverse and global enterprises with innovative products including Phenom Career Site, Chatbot, CMS, CRM, AI Scheduling, Video Assessments, Campaigns, University Recruiting, Talent Marketplace, Career Pathing, Gigs, Mentoring, and Referrals.
Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (3 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), five Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in AI for Business Impact,’ Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), and a regional Timmy Award for launching and optimizing HelpOneBillion.com (2020).
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005161/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
